Mechanistically, serglycin can activate several cancer-associated signaling pathways in other types of cancer, including mitogen-activated protein kinase (MAPK)/β-catenin signaling [12], transforming growth factor-β2 (TGF-β2) signaling via interaction with CD44 [13], and the NF-κB pathway [8]. The gene discussed is SRGN; the disease is cancer.